How to buy ImmunoGen stock - 12 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy ImmunoGen stock

Own ImmunoGen stock in just a few minutes.

ImmunoGen, Inc is a biotechnology business based in the US. ImmunoGen shares (IMGN) are listed on the NASDAQ and all prices are listed in US Dollars. ImmunoGen employs 79 staff and has a trailing 12-month revenue of around USD$132.3 million.

How to buy shares in ImmunoGen

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for ImmunoGen. Find the stock by name or ticker symbol: IMGN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until ImmunoGen reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of ImmunoGen, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of ImmunoGen. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

ImmunoGen share price

Use our graph to track the performance of IMGN stocks over time.

ImmunoGen shares at a glance

Information last updated 2021-04-08.
52-week rangeUSD$3.335 - USD$10.88
50-day moving average USD$8.6803
200-day moving average USD$6.8117
Wall St. target priceUSD$10.21
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.19

Buy ImmunoGen shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ImmunoGen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ImmunoGen financials

Revenue TTM USD$132.3 million
Gross profit TTM USD$17.7 million
Return on assets TTM -4.42%
Return on equity TTM -659.86%
Profit margin -33.54%
Book value $0.459
Market capitalisation USD$1.6 billion

TTM: trailing 12 months

Shorting ImmunoGen shares

There are currently 22.3 million ImmunoGen shares held short by investors – that's known as ImmunoGen's "short interest". This figure is 2.5% down from 22.9 million last month.

There are a few different ways that this level of interest in shorting ImmunoGen shares can be evaluated.

ImmunoGen's "short interest ratio" (SIR)

ImmunoGen's "short interest ratio" (SIR) is the quantity of ImmunoGen shares currently shorted divided by the average quantity of ImmunoGen shares traded daily (recently around 2.7 million). ImmunoGen's SIR currently stands at 8.16. In other words for every 100,000 ImmunoGen shares traded daily on the market, roughly 8160 shares are currently held short.

However ImmunoGen's short interest can also be evaluated against the total number of ImmunoGen shares, or, against the total number of tradable ImmunoGen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ImmunoGen's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 ImmunoGen shares in existence, roughly 110 shares are currently held short) or 0.1234% of the tradable shares (for every 100,000 tradable ImmunoGen shares, roughly 123 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against ImmunoGen.

Find out more about how you can short ImmunoGen stock.

ImmunoGen share dividends

We're not expecting ImmunoGen to pay a dividend over the next 12 months.

ImmunoGen share price volatility

Over the last 12 months, ImmunoGen's shares have ranged in value from as little as $3.335 up to $10.88. A popular way to gauge a stock's volatility is its "beta".

IMGN.US volatility(beta: 1.38)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ImmunoGen's is 1.38. This would suggest that ImmunoGen's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

ImmunoGen overview

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site